Variations in cell therapy reimbursement across the Big5EU Jesper Jorgensen and Panos Kefalas

First Page		Document Content
Date: 2016-04-19 09:57:26 Health economics Healthcare quality Costs Pricing Marketing Incremental cost-effectiveness ratio Quality-adjusted life year Cost-effectiveness analysis National Institute for Health and Care Excellence ICER Value-based pricing Costbenefit analysis		Variations in cell therapy reimbursement across the Big5EU Jesper Jorgensen and Panos Kefalas Add to Reading List Source URL: ct.catapult.org.uk Download Document from Source Website File Size: 1,30 MB Share Document on Facebook

	NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Health and Social Care Directorate Implementation Strategy Group Terms of reference 2016 Background NICE’s business plan sets a strategic objective for the Institute to DocID: 1v8RM - View Document
	A consultation to inform an update of the NHS Constitution: feedback report July 2015 DocID: 1r4BW - View Document
	Microsoft Word - GILEAD BRIEFING DocID: 1r2Vm - View Document
	Microsoft Word - valuing health DocID: 1qVy7 - View Document
	NATIONAL INFERTILITY GROUP REPORT MARCH 2016 417695_Fertility_p10.indd 1 DocID: 1qTLT - View Document